Cargando…
Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial
BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as ins...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496184/ https://www.ncbi.nlm.nih.gov/pubmed/28673277 http://dx.doi.org/10.1186/s12894-017-0243-1 |
_version_ | 1783247921538400256 |
---|---|
author | Peabody, John W. DeMaria, Lisa M. Tamondong-Lachica, Diana Florentino, Jhiedon Czarina Acelajado, M. Ouenes, Othman Richie, Jerome P. Burgon, Trever |
author_facet | Peabody, John W. DeMaria, Lisa M. Tamondong-Lachica, Diana Florentino, Jhiedon Czarina Acelajado, M. Ouenes, Othman Richie, Jerome P. Burgon, Trever |
author_sort | Peabody, John W. |
collection | PubMed |
description | BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as insufficient. A validated protein-based assay has been shown to predict tumor aggressiveness from prostate biopsy. The main objective of this study was to measure the clinical utility of this new assay in the management of early-stage prostate cancer. METHODS: One hundred twenty nine board-certified urologists were asked to participate in a randomized, two-arm experiment. We collected data over 2 rounds using simulated clinical cases administered via an online platform. The cases were all newly diagnosed Gleason 3 + 3 or 3 + 4 prostate camcer patients. Urologists in the intervention arm received a 15-min webinar on this protein-based assay and given assay test results for their simulated patients in round 2. Each case had a preferred recommendation of either active surveillance or active treatment. The measured outcome was rate of preferred recommendation, defined as urologists who recommended the proper treatment course. Analyses were done using difference-in-difference estimations. RESULTS: Using multinomial logistical regression, urologists who were given the assay results were significantly more likely to choose the preferred recommendation (active surveillance or active treatment) compared to controls (p = 0.004). These urologists were also significantly more likely to involve their patients in the treatment decision compared to controls (p = 0.001). CONCLUSIONS: By providing additional information to inform the physician’s treatment plan, a protein-based assay shows demonstrable clinical utility confirmed through a rigorous randomized controlled study design and regression analyses to test for effects. |
format | Online Article Text |
id | pubmed-5496184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54961842017-07-05 Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial Peabody, John W. DeMaria, Lisa M. Tamondong-Lachica, Diana Florentino, Jhiedon Czarina Acelajado, M. Ouenes, Othman Richie, Jerome P. Burgon, Trever BMC Urol Research Article BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as insufficient. A validated protein-based assay has been shown to predict tumor aggressiveness from prostate biopsy. The main objective of this study was to measure the clinical utility of this new assay in the management of early-stage prostate cancer. METHODS: One hundred twenty nine board-certified urologists were asked to participate in a randomized, two-arm experiment. We collected data over 2 rounds using simulated clinical cases administered via an online platform. The cases were all newly diagnosed Gleason 3 + 3 or 3 + 4 prostate camcer patients. Urologists in the intervention arm received a 15-min webinar on this protein-based assay and given assay test results for their simulated patients in round 2. Each case had a preferred recommendation of either active surveillance or active treatment. The measured outcome was rate of preferred recommendation, defined as urologists who recommended the proper treatment course. Analyses were done using difference-in-difference estimations. RESULTS: Using multinomial logistical regression, urologists who were given the assay results were significantly more likely to choose the preferred recommendation (active surveillance or active treatment) compared to controls (p = 0.004). These urologists were also significantly more likely to involve their patients in the treatment decision compared to controls (p = 0.001). CONCLUSIONS: By providing additional information to inform the physician’s treatment plan, a protein-based assay shows demonstrable clinical utility confirmed through a rigorous randomized controlled study design and regression analyses to test for effects. BioMed Central 2017-07-03 /pmc/articles/PMC5496184/ /pubmed/28673277 http://dx.doi.org/10.1186/s12894-017-0243-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Peabody, John W. DeMaria, Lisa M. Tamondong-Lachica, Diana Florentino, Jhiedon Czarina Acelajado, M. Ouenes, Othman Richie, Jerome P. Burgon, Trever Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial |
title | Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial |
title_full | Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial |
title_fullStr | Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial |
title_full_unstemmed | Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial |
title_short | Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial |
title_sort | impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496184/ https://www.ncbi.nlm.nih.gov/pubmed/28673277 http://dx.doi.org/10.1186/s12894-017-0243-1 |
work_keys_str_mv | AT peabodyjohnw impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial AT demarialisam impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial AT tamondonglachicadiana impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial AT florentinojhiedon impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial AT czarinaacelajadom impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial AT ouenesothman impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial AT richiejeromep impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial AT burgontrever impactofaproteinbasedassaythatpredictsprostatecanceraggressivenessonurologistsrecommendationsforactivetreatmentoractivesurveillancearandomizedclinicalutilitytrial |